Modality
mAb
MOA
BETi
Target
SGLT2
Pathway
RNA Splicing
GBM
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Feb 2026
Phase 1Current
NCT05968597
308 pts·GBM
2017-06→TBD·Active
NCT05404755
1,726 pts·GBM
2017-07→2026-02·Completed
2,034 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-141mo agoInterim· GBM
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Active
P1
Complet…
Catalysts
Interim
2026-02-14 · 1mo ago
GBM
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05968597 | Phase 1 | GBM | Active | 308 | ACR20 |
| NCT05404755 | Phase 1 | GBM | Completed | 1726 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |